Atelerix was the first Northern Accelerator spin-out, with CEO Dr Mick McLean recruited through the project’s ‘Execs into Business’ programme.
Atelerix has a transformative technology that offers the safe storage and transport of viable cells, including stem cells and cell-based assays, at ambient temperatures, which overcomes the barriers and limitations of the current need for cryo-shipping.
This breakthrough, a patented invention, provides dramatic improvements to an everyday process in a rapidly growing market.
The shipping of cells from one location to another for clinical and research use is a widespread and everyday practice, so there are many potential commercial applications for the technology, including:
- Businesses selling cells
- Discovery and testing of new drugs
- Developing cell therapies
- Storing stem cells